Telehealth use and its impact on clinical outcomes in patients with type 2 diabetes during the COVID ‐19 pandemic
Main finding · HbA1cResult — go to the resultAverage decrease 0.146 % 95% CI −0.178% to −0.1145%Authors' conclusion
Our findings suggest that telehealth services contributed to better glycaemic control and management of other clinical outcomes in patients with type 2 diabetes during the pandemic. Factors unmeasured in this study would need to be further explored to better understand the impact of telehealth.
Study context
- Population
- Patients with T2D during the COVID-19 pandemic, Research Action for Health Network (REACHnet) electronic health records
- Exposure
- Telehealth use vs in-person care only during the COVID-19 pandemic
- Outcome
- HbA1c
Methodological detailsquasi-experimental difference-in-difference, propensity-score weighting, electronic health records (REACHnet)
- Quasi-experimental difference-in-difference
- Propensity-score weighting
- Electronic health records (REACHnet)
Main finding
As reported in the abstract
over time
Average decrease
0.146 %
95% CI −0.178% to −0.1145%
P < 0.001
Observational data: associations, not effects.
Further findings
Proportion of patients with average HbA1c >7%
- Decrease in the treatment group relative to the comparison group
- 0.023 (95% CI −0.034, −0.011; P < 0.001)
LDL cholesterol, diastolic BP and BMI
- Modest benefits in LDL cholesterol, diastolic BP and BMI control associated with telehealth use
Original publication
Telehealth use and its impact on clinical outcomes in patients with type 2 diabetes during the COVID ‐19 pandemic. Diabetes Obes Metab. Published 19 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →